Company Info

Number of Employees

8234

Ticker

532523 (BSE)

Revenue

$546.3

Visit Website

Biocon

CDMO

Overview

Biocon, India’s largest biotech company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. As an innovation led organization focused on providing affordable access, they have leveraged their inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules APIs and formulations and complex biologics – both novels and biosimilars – including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs.

Company Services

Services/CapabilitiesCDMO

+ Development Services

Analytical Development & Validation
Bioanalytical Services
Preformulation/Formulation
Process Development & Validation
Stability Testing

+ Drug Product Manufacturing

Lyophilized Products Manufacturing

+ Packaging

Prefilled Syringes/Cartridges/Pen Devices

Company Info

Biocon

Overview

Company Services

Services/CapabilitiesCDMO

Contributions

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review

Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

Sandoz – Biocon Deal One More Sign That U.S. Biosimilars Have Arrived

First Biosimilar to Treat Breast and Stomach Cancers Approved

FDA Recommends Approval of Trastuzumab Biosimilar